Table 3.
Estimated number of Queensland patients with MROs and deaths from sepsis
| 2021 | 2022 | 2023 | 2024 | 2025 | |
| Number of annual hospitalisations | 1 639 888 | 1 639 888 | 1 639 888 | 1 639 888 | 1 639 888 |
| Number of HAIs | 162 349 | 162 349 | 162 349 | 162 349 | 162 349 |
| Number of HAIs from MROs of interest | 58 141 | 58 141 | 58 141 | 58 141 | 58 141 |
| Number of patients infected with MROs* | |||||
| MRSA | 3223 | 3290 | 3357 | 3424 | 3491 |
| ESBL Escherichia coli | 752 | 881 | 1009 | 1138 | 1267 |
| VRE | 3551 | 3288 | 3025 | 2762 | 2499 |
| ESBL Klebsiellapneumoniae | 292 | 364 | 435 | 507 | 578 |
| CPE | 128 | 128 | 128 | 128 | 128 |
| CRAB | 57 | 57 | 57 | 57 | 57 |
| Total MROs of concern | 8003 | 8008 | 8012 | 8017 | 8021 |
| Total number of patients colonised with MROs | 89 536 | 84 801 | 80 067 | 75 332 | 70 598 |
| Total number of patients expected with infections/colonisations | 97 539 | 92 809 | 88 079 | 83 349 | 78 619 |
| Deaths from sepsis | 2032 | 1982 | 1932 | 1881 | 1831 |
*Adjusted for change in drug resistance rate.
CPE, carbapenemase-producing Enterobacterales; CRAB, carbapenem-resistant Acinetobacter baumannii; ESBL, extended spectrum beta-lactamases; HAI, healthcare-associated infection; MRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci.